Dexus reviews healthcare fund options: 90% redemptions test Dexus stock

Published on 10/25/2026 at 00:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The healthcare fund review covers asset sales and new capital structures on October 23, 2026. Dexus stock also faces an October 28 AGM.

Liquidity review and earnings outlook

On October 23, 2026, Dexus was reported to have appointed Denison Partners to review healthcare fund options.
Fiscal year 2026 adjusted funds from operations reached AUD 483.90 million, while fiscal year 2027 guidance is 37.50 to 39.50 cents per security.
Dexus had a market capitalization of AUD 6.1 billion as of October 23, 2026.
Dexus's annual meeting is scheduled for October 28, 2026.

Dexus, AU000000DXS1, Illustration mit AI erstellt.

Dexus (AU000000DXS1) was reported to have appointed Denison Partners on October 23, 2026, to review options for its healthcare property fund after investors sought redemptions, according to Simply Wall St. The reported options include asset sales, alternative capital structures and a potential wind-down.

Liquidity pressure meets a wider platform

The review matters because Dexus combines property ownership with third-party funds management. Its investor-relations page lists a real asset portfolio of AUD 51.4 billion, third-party funds under management of AUD 36.1 billion and a group real estate development pipeline of AUD 12.8 billion, all as of June 30, 2026, according to Dexus. A fund-level liquidity decision therefore has implications beyond one vehicle, particularly for confidence in fee-generating capital.

On October 23, 2026, Dexus had a market capitalization of AUD 6.1 billion, while its quoted ASX range was AUD 5.30 to AUD 7.73. The dated market figures frame the review against a stock that remains below its yearly high, without turning the fund process into a forecast.

What does the review mean for cash earnings?

The immediate comparison is with Dexus's earnings outlook. Land.com.au reported that adjusted funds from operations reached AUD 483.90 million, or 45.00 cents per security, in fiscal year 2026, while fiscal year 2027 guidance was set at 37.50 to 39.50 cents per security, with distributions held at 37.00 cents, as reported on September 25, 2026 by Land.com.au. The lower guidance range places more weight on execution, financing costs and the treatment of assets under review.

Three dates explain the setup

On August 20, 2026, Dexus reported fiscal year 2026 adjusted funds from operations of AUD 483.90 million, according to Land.com.au. On September 24, 2026, Dexus confirmed an annual meeting for October 28, 2026, according to FT.com. On October 23, 2026, the healthcare fund review was reported after redemption requests reached 90 percent, according to Simply Wall St.

Next date for security holders

Dexus's next substantiated corporate date is October 28, 2026, when the annual meeting is scheduled to consider the FY27 long-term incentive grant for Chief Executive Ross Du Vernet. The October 1, 2026 notice set the proposed grant at 527,240 performance rights, based on a value of AUD 5.69 per right, according to TradingView.

Euro reference remains dated

The last available euro price comes from Tradegate and stood at EUR 3.52 on October 19, 2026 at 2:39 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Dexus stock.